TW384224B - Method of preparing submicron particles of a therapeutic or diagnostic agent - Google Patents

Method of preparing submicron particles of a therapeutic or diagnostic agent Download PDF

Info

Publication number
TW384224B
TW384224B TW084104440A TW84104440A TW384224B TW 384224 B TW384224 B TW 384224B TW 084104440 A TW084104440 A TW 084104440A TW 84104440 A TW84104440 A TW 84104440A TW 384224 B TW384224 B TW 384224B
Authority
TW
Taiwan
Prior art keywords
patent application
item
particle size
abrasive
average particle
Prior art date
Application number
TW084104440A
Other languages
English (en)
Inventor
David A Czekai
Larry P Seaman
Original Assignee
Nano Sys Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nano Sys Llc filed Critical Nano Sys Llc
Application granted granted Critical
Publication of TW384224B publication Critical patent/TW384224B/zh

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/895Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896Chemical synthesis, e.g. chemical bonding or breaking
    • Y10S977/897Polymerization
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915Therapeutic or pharmaceutical composition
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T24/00Buckles, buttons, clasps, etc.
    • Y10T24/40Buckles
    • Y10T24/4051Garment shielded

Description

經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(1 ) 發明莆景 各種磨媒,如不銹鋼、矽酸锆、氧化錐、玻璃等,通常 呈球形珠粒型式,常應用於各種磨機中,包括中级磨機κ 輾磨物質。於過去,已盡力壓控制藥學組成物中藥物粒子 之大小及大小範圍,所利用的各種方法包括各種輾磨技術 ,如空氣噴射式輾磨及濕式輾磨。然而,由於和摻雜物有 關,藥學技藝在面對輾磨技術上似乎有成見,特別是濕式 輾磨。如,於製備供口服及腸外應用之藥物時,希望加重 金屬為例之總污染'在約10 PPmM下。在輾磨腸外產物方面 ,控制及減低污染之需求特別迫切,這是由於和污染物注 射有關之潛在安全性議題之故。
Liversidge等人,美國專利No. 5,145,684 ,及歐洲_專 利案498,492 ,描述由藥物物質或X射線對比劑姐成之可 分散的粒子,在其表面吸附有表面修飾劑,且含量足Μ維 持有效平均粒子在約400毫徽米Μ下。粒子之製備係將藥 物或顯影劑分散於液體分散介質中,並在剛性磨媒存在下 行濕式輾磨。
Bruno et al.,共同之美國專藥學列07/981,639 (公告 於19 92年11月25日),標題為輾磨藥學物質之方法,其中 揭示用於細碎輾磨之藥學組成物中之聚合磨媒。Bruno等 人揭示介質使用之大小範圍在0.卜3毫米間( 100-3000微 米)。在操作實例中特別揭示之介質具有0.3-0.6毫米( 300-600微米)範圍之平均粒子大小。 在演練由Liversidge等人及Bruno等人所述之方法時, —4 一 本紙張尺度適用中國國家標隼(CNS ) A4規格(21〇X297公羞) Λ請先濶讀背面之注意事項再填寫本頁) 裝·
、tT 經濟部中央標準局員工消費合作社印製 Α7 Β7 五、發明説明(2 ) 在某些狀況下可得含有治療劑及診斷劑其粒子大小小至g 100毫微米之分散相。然而,於許多應用時,如欲進一步 增加生物利用率及/或對準特別的姐織部位時,製造其粒 子大小在100毫微米K下且無未可接受之摻雜物之分散相 是高度有益的。 發明要點 吾等發規,可製造無未可接受之摻雜物,且極细碎粒子 ,如小於100毫微米Μ下之治療劑及診斷劑,其中係在平 均粒子大小少於約75微米之磨媒存在下進行輾磨。 更特別地,依據本發明,提出製造治療劑或診斷劑粒子 之方法,此方法包括在平均粒子大小少於約75微米之磨媒 存在下輾磨作用物。 本發明特別有益之特色是提出製備極细碎治療劑及診斷 劑粒子,且無可接受之摻雜物及/或褪色之方法。 本發明又一優點特色是提出精细輾碎治療劑及診斷劑之 方法,此方法產生較少的熱及減少潛在的與熱有闥之問題 、如化學不穩定性及污染。 本發明另一有益特色是提出可改進pH值控制之精細輾碎 藥物及顯像劑之方法。 其他有益特色一Μ參考K下較佳具體實例之說明將可十 分明白。 較佳具體實例之說明 本發明有部份是依據意外的發現,即在極细碎磨媒存在 下輾磨可製備極细碎的治療劑及診斷劑粒子,且無未可接 本紙張尺度適用中國國家標準(CNS ) Μ規格(210X297公釐) 、(請先擱讀背面之注意事項再填寫本頁) 裝_ 訂 A7 B7 五、發明説明(5 ) 受之摻雜物。而本發明此中之描述是配合其較佳之利用性 、即關於治療劑用於藥學姐成物中,及診斷劑用於翳學診 斷組成物中,也咸信其可用於其他應用上,如輾碎粒子應 用於化粧品組成物中,其中欲求極細碎粒子,且可關心到 污染問題。 在本發明方法中,製成亞微细粒型式之治療或診斷劑, 係在平均粒子大小少於約75微米之磨媒存在下輾磨作用物 Ο 於較佳具體實例中,磨媒可包括聚合樹脂粒子,較好實 質上是球形、如珠粒狀。然而,呈其他非球形之磨媒預期 也可用於實行本發明。 經濟部中央標準局員工消費合作社印製 :------_---.萍 11 .1' 、請先裯讀背面之注意事項再填寫本頁). 一般而言,在此適用之聚合樹腊是化學及物理上惰性的 ,實質上無金屬、溶劑及單體,且具足夠的硬度及脆性使 其避免在輾磨中被碎削或壓碎。適合的聚合樹脂包括交聯 的聚笨乙烯類,如聚笨乙烯與二乙烯基笨交聯,苯乙婦共 聚物,聚丙烯酸酯類的聚甲基丙烯酸甲酯、聚碳酸酯類, 聚縮醛類,如Delrin,乙烯基氯聚合物及共聚物,聚醋 類’聚醯胺類,聚(四氟乙烯類),如鐵弗隆,及其他的氟 聚合物’高密度聚乙烯類,聚丙烯類,纖維素醚類及酯類 、如醋酸纖維素、聚羥異丁烯酸酯、聚丙烯酸羥乙基酯, 含有矽氧之聚合物、如聚矽氧烷類等。聚合物可被生物降 解。生物可降解之聚合物實例包括:聚交酯、聚乙交醅、 丙交酿及乙交酯之共聚物,聚酐類,聚異丙烯酸經乙基酯 ’聚碳酸亞胺基醋、聚(N-醜基經基腩胺酸)酯類,聚( -6 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 A7 ___B7_^______ 五、發明説明(斗) N-棕櫚醯基羥基脯胺酸酯,乙烯-醋酸乙烯基酯共聚物, 聚(原酸酯),聚(己内酯),及聚(磷腈)。在生物可降解之 聚合物中,介質本身之污染可於注體内有益地代謝成為生 物學上可接受之產物,而自體內消除。 聚合樹脂之密度可由0,8至3.0克/公分3 。較高密度 的樹脂為較佳,因同樣地咸信可提供更有效的粒子大小減 低。 再者,申請人咸信,本發明可配合製成適合粒子大小的 各種無機磨媒來演練。此種磨媒包括氧化锆,如95% ZrO Μ鎂穗定,矽酸锆,玻璃,不銹鋼,二氧化鈦,二氧化鋁 ,及95%Zr〇M釔穩定。 介質之大小範圍可高達約100微米。於精细輾碎時,粒 子較好少於約75微米,更好少於約50微米,且最好少於約 25微米。Μ粒子大小約5微米之介質可達到極佳之粒子大 小減少。 輾磨過程可Μ是一種乾式過程,如乾式滾動輾磨過程, 或濕式過程,如,濕式輾磨。於較佳具體實例中,本發明 依據美國專利No. 5,145,684及歐洲專利498,482中所述 之濕式輾曆過程來演練。因此,濕式輾磨過程中可配合液 體分散介質及表面修飾劑來演練,如這些專利案中所述一 般。有用的液體分散介質包括水,鹽水溶液,乙醇,丁醇 ,己烷,甘醇等。表面修飾劑可讓自己知之有機及無機藥 學賦形劑,如美國專利案No . 5 , 145,684中所述,且含量 在0.:1-90¾ ,較好卜80% ,按乾粒子總重計。 -7- 本紙張尺度適用中國國家標準(CNS ) A4g ( 210X297公釐) ----------^1-----tr------0 „(請先-H讀背面之注意事項再填寫本頁). 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(5 ) 在較佳具體實例中,可將治療或診斷劑製成亞微細粒或 毫微細碎,如少於約5 00毫微米。申請人已証明,可製成 平均粒子少於約30 0毫微米之粒子。在某些具體實例中, 已依據本發明製成平均粒子大小少於1〇〇毫微米之粒子。 特別驚人且意外的是,此種细碎粒子可在無可接受之摻雜 物下製備。 輾磨可在任何適合的磨機中進行。適合的輾磨機包括空 氣噴射之磨機、軋製機、球型磨機、磨碎機,振動磨機, 行星式磨機,砂磨機及珠粒磨機。當磨媒是聚合樹脂時, 高能量的中级磨機尤其佳。本發明也可配合高速泡罩來演 練,如Cowles,泡罩,旋轉一固定混合機,或其他可遞送 高流體速率及高切力之傳統混合機。 磨媒,治療及/或診斷劑,視所需的液體分散介質,及 在輾磨容器中存在之表面修飾劑,其中較佳之比例可在大 範圍中變化。如一旦選定特殊之藥物或顯影劑,可選擇磨 媒之大小及密度,磨機之型式等。過程可Μ連續、批次或 半批次模式進行。在髙能量中级磨機中’希望曆媒可充滿 磨室體積之70-90¾。另一方面,在軋製機中,通常希望磨 機容器可留下一半K充滿空氣,其餘的髏積包括磨媒及若 存在之液體分散介質。如此使"jfo上容容器内有串連效應而 可有效地輾磨。然而,當在濕式輾磨有起泡問題時,容器 可完全充滿液體分散介質。 磨耗時間可有大的變化,且主要依特殊治療或診斷劑’ 所選用之機械工具及逗留時間,最初及欲求之最終粒子大 -8 ~ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -----------I.装11 ,(請先濶讀背面之注意事項^:填寫本頁)
<1T 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(6 ) 小等等而定。如軋製機,處理時間可由數天至數週。另一 方面,少於8小時之逗留時間通常需使用高能量之分散劑 及/或中級磨機。 一旦磨耗完全,磨媒利用傳統的分離方法與經輾磨之粒 子產物分離(圼乾或液體分散型式),而過滹,過篩等。 本發明可K各樣的治療及診斷劑來演練。在乾式輾磨例 .中,藥物及顯影劑必須是可形成固體微粒者。於濕式輾磨 例中,藥物及顯影劑必須不良溶解及分散於至少一種液體 介質中。所讅”不良溶解”表示治療劑或診斷劑在液體分散 介質中之溶解度(如水中)少於約10毫克/毫升,且較好少 於約1毫克/毫升。較佳之液體分散介質是水。另外,本 發明可Μ其他的液髏介質來演練。治療及診斷劑較好是一 種有機、晶狀物質。 適合的治療劑及治療劑類別,述於美國專利Ν 〇 . 5,145,684中,且包括〇3以2〇1(丹諾),5〇(,17〇£-1’-(甲 基磺醯基)-1'Η -孕-20 -炔應[3,2-c]吡唑-17-醇,喜樹鹼 (Camptothecin)、哌藤硫胺,(piposulfam)、脈醯硫燒 (piposu.l fan)、那玻辛(naproxen)及苯妥英(phenytion )°其他適合的藥物包括述於PCT國際案PCT/US93/05082之 NSAIDs (發表於1993年12月23日),及述於歐洲專利案 577,215中之抗癌藥(發表於1 993年1月5日)。
適合的診斷劑包括碘化芳族酸之衍生物,如3,5 -雙乙醸 基醯胺-2,4,6-三碘笨甲酸乙酯(WIN 8883),(3,5-雙( 乙醯基胺基)-2,4,6 -三碘苄醯氧基)乙酸乙酯(WIN ~ 9 ~ 本紙張尺度適用中國國家標準(CNS ) M規格(2丨〇 X 297公釐) (請先閣讀背面之注意事項再填寫本頁) 裝. 訂 第84104440號專利申請察 A 7
中文說明書修正頁(87年':1月)L 五、發明説明( - 129 01),2-(雙(乙醯基胺基)_2,4,6-三碘苄醯氧基)丁酸 乙酯,(WIN 16318),6-乙氧基-6-酮己基-3,5-雙(乙藤 胺基)-2,4,6-三碘苯甲酸g旨(WIN 67722)。其他適合的顯 影劑述於美國專利案No . 5 , 260 , 478 ,美國專利案No . 5,264,610及歐洲專利案498,482中。 Μ下實例進一步說明本發明。 置~例1 企·..質大小對Ha n a ^ 1 (再諾)分散相夕聚绺 經濟部中央標準局員工消費合作社印製 製備丹諾預混分散相,係混合30% W/W丹諾(2-10微米 平均大小粉末)、10¾聚乙烯吡咯啶酮(PVP)具平均分子 量15, 000及水。製備與二乙烯基等交聯之聚笨乙烯珠粒 (20¾笨乙烯,80%二乙烯基笨),即以傳统的聚合作用技 術製成平均直徑5,25 , 50 , 200及450微米。450微米珠 粒加至 Dyno-ίΉΙΙ (機型:.KDL_Special,由 Chicago Boiler出品)之輾磨室中(300毫升,316级不銹鋼)。對照 姐分散相之製備係將預混分散相輾磨達120分鐘逗留時間 。輾磨後,對照姐分散相以水稀釋至5%丹諾,1.5¾ PVP之 最終澹度,並進一步在高能量之磨碎機中,利用各種大小 的聚笨乙烯介質輾磨60分鐘再循環時間)。分散相以5微 米過滤與介質分離,並以毛细流體動力分级分離(CHDF)如 下般偵測粒子大小: 10- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 S84224 at __^_B7___ 五、發明説明(8 ) 重量平均 介質大小(微米)丹諾粒子大小(毫微米) 對照組 149 450 105 200 86 50 80 25 92 (可能的絮凝) 這些結果顯示,依據本發明可製備平均大小少於1〇〇毫微 米之粒子。 奮例2 U 5微米±小之介督_磨 在接下來的實例中,使用上述之5微米聚苯乙烯介質, 並在類似上逑之輾曆條件。生成的分散相粒子大小為105 毫微米。完全想不到的是K此細碎顯微聚合介質可達到極 佳之一致性。在水溶液中,5微米介質對肉眼而言乳狀溶 液狀。 實例3 刺用細碎聚合介質在0.3弁DvnoMillt^aa鱺磨 過稈 製成預混分散相,即以5.0!«丹諾、1.5%1卩卩及93.5%水 之比例混合微细化之丹諾粉末(2 - 1 0微米平均大小)與p V P 水溶液(平均MW = 1 5,000)。此預混分散相取292克混合 379.6克有二乙烯基苯交聯之聚笨乙烯(20:80 w/w)磨媒 ,通稱大小為50微米。此混合的混合物經由〇.3升Dyno-Mill, 在 3200 rpm(100 公分 3/分) 再 循環歷 6〇 分 ( 逗留時 間)。輾磨後,介質利用10微米濾膜分離。輾磨弦以 -11- 本紙張尺度適用中國國家標準(CNS ). A4規格(210X297公釐_) ----1!----, ^-----——ίτ------0 > (請先Μ讀背面之注意事項再填寫本頁) S84224 A7 B7 五、發明説明(9 ) CHDF偵測粒子大小。粒子大小分佈顯示35毫微米之重量平 均粒子大小。 普例4· 刺ffi細碎聚会介皙宑0.6弁DvnnMi丨1由逋镰齦磨 過稈 製備預混分散相,係Μ 5.0%丹諾、1.5¾ PVP及93.5¾ 水之比例混合微细化之丹諾粉末(2 - 1 〇微米平均大小)與 PVP水溶液(平均MW = 15,000)。此預混分散相取2768克琨 合M3324克有二乙烯基苯交聯之聚笨乙烯(20:80 w/\?)並 經0.16升DynoMill,在3200 rpm(100公分3 /分)下再循環 歷60分鐘逗留時間。輾磨後,介質M10微米濾膜分雛。此 批次之粒子大小並未測量,但由顯微檢查顯示平均大小似 乎在100毫微米K下。 本發明由某些較佳具體實例之特別參考已詳細描述,但 要了解在本發明精義及範疇下可達成變化及修飾。 請 先 讀 背 面 之 注 意 事 項 再 經濟部中央標準局員工消費合作社印製 -12 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)

Claims (1)

  1. A8 B8 第84104440號專利申請案 中文申請專利範圍修正本(路年5月)g| 年周園 六、申請專利範圍
    S842B4 1. 一種輾磨治療或診斷劑粒子之方法,包括在平均粒子 大小低於約100微米之剛性磨媒之存在下輾磨該劑, 其中藉忒輾磨方法製造之治療或診斷劑粒子具有低於 約5 0 0 nm之平均粒子大小,且其中該經輾磨劑組合物 不包含因磨媒變質所造成不可接受之污染。 2. 根據申請專利範圍第丨項之方法,其中藉該輾磨方法製造 之治療或診斷劑粒子具有低於約丨〇〇 nm之平均粒子大 先 聞 讀 背 ιδ 之 注 意 事 項 再 装 3.根據申請專利範圍第丨項之方法,其中該方法是濕式 輾磨 過程 經濟部中央標準局貝工消費合作社印製 4. 根據申請專利範圍第丨項之方法,其中該治療劑是丹諾 (Danazol)。 5. 根據申請專利範圍第丨項之方法,其中該磨媒具有平均粒 子大小低於約7 5微米。 6 ·根據申请專利範圍第5項之方法’其中該磨媒具有平均粒 子大小低於約5 0微米。 7 ·根據申请專利圍第6項之方法’其中該磨媒具有平均粒 子大小低於約2 5微米。 8.根據申請專利範圍第7項之方法’其中該磨媒具有平均粒 子大小約5微米。 9 .根據申請專利範圍第1項之方法,其中該剛性磨媒是一種 聚合樹脂。 10.根據申請專利範圍第9項之方法,其中該聚合樹脂是與二 乙錦·基苯交聯的聚苯乙稀·。 本紙張尺度適用中國國家標隼(CNS〉A4規格(21〇x:297公爱) 訂 Ι^Β 經濟部中央標準局員工消費合作社印袋 A8 B8 C8 _n%mu_ 六、申請專利範圍 11. 根據申請專利範圍第9項之方法,其中該聚合樹脂是聚甲 基異丁烯酸酯。 12. 根據申請專利範圍第1項之方法,其中該輾磨係發生在選 自包括鬲剪切力分散機、轉子-定子混合器及輾磨機之機 器。 13. 根據申請專利範圍第12項之方法,其中該輾磨機係選自包 括:空氣噴射磨機、軋製機、球形磨機、磨碎機' 振動磨 機、行星式磨機、砂磨機、及珠粒磨機。 14. 一種製備治療或診斷劑粒子之方法,包括在平均粒子 大小低於約1 0 0微米之剛性磨媒之存在下輾磨該劑, 其中藉邊輾磨方法製造之治療或診斷劑粒子具有低於 約5 00 nm之平均粒子大小,且其中該經輾磨劑組合物 不包含因磨媒變質所造成不可接受之污染。 15. 根據申请專利範圍第1 4項之方法,其中藉該輾磨方法製 造之治療或診斷劑粒子具有低於約1〇〇 nm之平均粒子 大小。 16·根據中請專利範園第14項之方法’其中該方法是濕式振磨 過程。 Π_根據中請專利範園第14項之方法,其中該治療劑是丹諾 (Danazol)。 18· «tH利範圍第14項之方法’其中該磨媒具有平均 粒子大小低於約7 5微米。 19·«中請專利範目第18項之方法’其中該磨媒具有平均粒 子大小低於約5 0微米。 ---------^----·I--------¾ (請先聞讀肯面之注意事項再填寫本頁) U—_Γ_r- ------- . -2-
    A8 B8 C8 D8 S84224 申請專利範圍 20·根據中請專利範圍第19項之方法’其中該磨媒具有平均粒 子大小低於約25微米。 21·根據中請專利範園第2G項之方法’其中該磨媒具有平均粒 子大小約5微米。 22.根據申請專利範圍第14項之方法,其中該剛性磨媒是一種 聚合樹脂。 23·根據申請專利範圍第22項之方法,其中該聚合樹脂是與二 乙烯基苯交聯的聚苯乙烯。. 24. 根據申請專利範圍第22項之方法,其中該聚合樹脂是聚甲 基異丁缔酸酯。 25. 根據申請專利範圍第14項之方法,其中該輾磨係發生在選 自包括尚剪切力分散機、轉子-定子混合器及輾磨機之機 器。 26. 根據申請專利範園第2 5項之方法’其中該輾磨機係選自包 括:空氣噴射磨機、軋製機、球形磨機、蘑碎機、振動磨 機、行星式磨機、砂磨機、及珠粒磨機。 (諳先閱讀背面之注$項再填寫本頁) 袈. *-ST 經濟部中央標準局員工消費合作社印褽 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X297公釐)
    申請曰期 84.05.03 案 號 84104440 類 別. 以上各攔由本局填柱) A4 C4 (88年5月修正頁) 384224 新型 %專利説明書 中 文 發明 新型 名稱 英 文 姓 名 國 籍 製備治療或診斷劑之亞微粒子之方法 "METHOD OF PREPARING SUBMICRON PARTICLES OF A THERAPEUTIC OR DIAGNOSTIC AGENT" 1. 大衛‘ A *卡茲凱 2. 賴利· P ·西門 裝 發明 創作 人 1-2均美國 住、居所 1. 美國紐約州羅徹斯特市史谷特街343號 2. 美國紐約州羅徹斯特市史谷特街343號 訂 姓 名 (名稱) 美商内諾糸統公司 線 經濟部智,¾时產;工消費合作社印製 國 籍 住、居所 (事務所) 代表人 姓 名 美國 美國賓州卡列維市南卡列維路1250號 拉瑞·A·史德森 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 第84104440號專利申請察 A 7 中文說明書修正頁(87年':1月)L 五、發明説明( - 129 01),2-(雙(乙醯基胺基)_2,4,6-三碘苄醯氧基)丁酸 乙酯,(WIN 16318),6-乙氧基-6-酮己基-3,5-雙(乙藤 胺基)-2,4,6-三碘苯甲酸g旨(WIN 67722)。其他適合的顯 影劑述於美國專利案No . 5 , 260 , 478 ,美國專利案No . 5,264,610及歐洲專利案498,482中。 Μ下實例進一步說明本發明。 置~例1 企·..質大小對Ha n a ^ 1 (再諾)分散相夕聚绺 經濟部中央標準局員工消費合作社印製 製備丹諾預混分散相,係混合30% W/W丹諾(2-10微米 平均大小粉末)、10¾聚乙烯吡咯啶酮(PVP)具平均分子 量15, 000及水。製備與二乙烯基等交聯之聚笨乙烯珠粒 (20¾笨乙烯,80%二乙烯基笨),即以傳统的聚合作用技 術製成平均直徑5,25 , 50 , 200及450微米。450微米珠 粒加至 Dyno-ίΉΙΙ (機型:.KDL_Special,由 Chicago Boiler出品)之輾磨室中(300毫升,316级不銹鋼)。對照 姐分散相之製備係將預混分散相輾磨達120分鐘逗留時間 。輾磨後,對照姐分散相以水稀釋至5%丹諾,1.5¾ PVP之 最終澹度,並進一步在高能量之磨碎機中,利用各種大小 的聚笨乙烯介質輾磨60分鐘再循環時間)。分散相以5微 米過滤與介質分離,並以毛细流體動力分级分離(CHDF)如 下般偵測粒子大小: 10- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) A8 B8 第84104440號專利申請案 中文申請專利範圍修正本(路年5月)g| 年周園 六、申請專利範圍
    S842B4 1. 一種輾磨治療或診斷劑粒子之方法,包括在平均粒子 大小低於約100微米之剛性磨媒之存在下輾磨該劑, 其中藉忒輾磨方法製造之治療或診斷劑粒子具有低於 約5 0 0 nm之平均粒子大小,且其中該經輾磨劑組合物 不包含因磨媒變質所造成不可接受之污染。 2. 根據申請專利範圍第丨項之方法,其中藉該輾磨方法製造 之治療或診斷劑粒子具有低於約丨〇〇 nm之平均粒子大 先 聞 讀 背 ιδ 之 注 意 事 項 再 装 3.根據申請專利範圍第丨項之方法,其中該方法是濕式 輾磨 過程 經濟部中央標準局貝工消費合作社印製 4. 根據申請專利範圍第丨項之方法,其中該治療劑是丹諾 (Danazol)。 5. 根據申請專利範圍第丨項之方法,其中該磨媒具有平均粒 子大小低於約7 5微米。 6 ·根據申请專利範圍第5項之方法’其中該磨媒具有平均粒 子大小低於約5 0微米。 7 ·根據申请專利圍第6項之方法’其中該磨媒具有平均粒 子大小低於約2 5微米。 8.根據申請專利範圍第7項之方法’其中該磨媒具有平均粒 子大小約5微米。 9 .根據申請專利範圍第1項之方法,其中該剛性磨媒是一種 聚合樹脂。 10.根據申請專利範圍第9項之方法,其中該聚合樹脂是與二 乙錦·基苯交聯的聚苯乙稀·。 本紙張尺度適用中國國家標隼(CNS〉A4規格(21〇x:297公爱) 訂 Ι^Β
TW084104440A 1994-05-25 1995-05-03 Method of preparing submicron particles of a therapeutic or diagnostic agent TW384224B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24978194A 1994-05-25 1994-05-25

Publications (1)

Publication Number Publication Date
TW384224B true TW384224B (en) 2000-03-11

Family

ID=22944965

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084104440A TW384224B (en) 1994-05-25 1995-05-03 Method of preparing submicron particles of a therapeutic or diagnostic agent

Country Status (15)

Country Link
US (1) US5862999A (zh)
EP (1) EP0760653B1 (zh)
JP (1) JPH10501709A (zh)
AT (1) ATE196601T1 (zh)
AU (1) AU2550195A (zh)
CA (1) CA2190966C (zh)
DE (1) DE69518981T2 (zh)
DK (1) DK0760653T3 (zh)
ES (1) ES2152401T3 (zh)
GR (1) GR3035040T3 (zh)
IL (1) IL113852A0 (zh)
MY (1) MY112458A (zh)
PT (1) PT760653E (zh)
TW (1) TW384224B (zh)
WO (1) WO1995031974A1 (zh)

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
PT1126826E (pt) * 1998-11-02 2008-11-25 Elan Pharma Int Ltd Composição de metilfenidato de libertação modificada multiparticulada
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
JP4156807B2 (ja) * 1999-06-01 2008-09-24 エラン ファーマ インターナショナル,リミティド 小型ミル及びその方法
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
ES2334435T3 (es) 2000-04-26 2010-03-10 Elan Pharma International Limited Aparato de molienda humeda higienica.
JP4763957B2 (ja) 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
ATE424811T1 (de) 2000-08-31 2009-03-15 Jagotec Ag Gemahlene partikel
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
ATE374641T1 (de) * 2001-01-26 2007-10-15 Schering Corp Kombinationen vom ppar-aktivator fenofibrat mit dem hemmer der sterol-absorption ezetimibe zur behandlung von kardiovaskulären indikationen
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
CA2449490C (en) * 2001-06-05 2010-10-05 Elan Pharma International Limited System and method for milling materials
ATE291899T1 (de) * 2001-06-22 2005-04-15 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
AU2002337692B2 (en) * 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US20040015519A1 (en) * 2001-10-15 2004-01-22 Yukitoshi Maeda Content delivery server and content delivery system having the same
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030152519A1 (en) * 2001-11-07 2003-08-14 Reinhard Koenig Methods for vascular imaging using nanoparticulate contrast agents
CA2471400A1 (en) 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
JP2005526095A (ja) * 2002-03-20 2005-09-02 エラン ファーマ インターナショナル,リミティド 脆砕性の低い急速溶解投与剤型
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
WO2003086354A1 (en) 2002-04-12 2003-10-23 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7763278B2 (en) * 2002-06-10 2010-07-27 Elan Pharma International Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
EP1551457A1 (en) * 2002-07-16 2005-07-13 Elan Pharma International Limited Liquid dosage compositions of stable nanoparticulate active agents
WO2004014342A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
DE60334924D1 (de) * 2002-09-11 2010-12-23 Elan Pharma Int Ltd Anoteilchengrösse
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
TW553767B (en) * 2002-12-30 2003-09-21 Ind Tech Res Inst Method for producing ultra-fine dispersion solution
CA2511995C (en) 2003-01-02 2012-03-13 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル,リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601669B1 (en) * 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7140567B1 (en) * 2003-03-11 2006-11-28 Primet Precision Materials, Inc. Multi-carbide material manufacture and use as grinding media
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
US20060141038A1 (en) * 2003-06-27 2006-06-29 Bioprogress S. P. A. Composite product obtainable by cogrinding of a active principle with a copolymer n-vinyl-2 pyrrolidone/vinyl-acetate
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US7879360B2 (en) * 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
US20050258288A1 (en) * 2003-11-26 2005-11-24 E. I. Du Pont De Nemours And Company High pressure media milling system and process of forming particles
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
JP2008504097A (ja) * 2004-07-01 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ナノ粒子を含有する医薬組成物の調製
EP1621200A1 (en) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate
DE102004040368B3 (de) * 2004-08-20 2006-02-23 Juhnke, Michael, Dipl.-Ing. Mahlkörper zur Herstellung feinstkörniger Produkte
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
KR20070118224A (ko) * 2005-01-06 2007-12-14 엘란 파마 인터내셔널 리미티드 나노입자형 칸데사르탄 제제
EP1853234A2 (en) 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
CN101175480A (zh) * 2005-03-16 2008-05-07 伊兰制药国际有限公司 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂
MX2007011495A (es) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones de bifosfonato en nanoparticulas.
EA200702049A1 (ru) * 2005-03-23 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции наночастиц кортикостероидов с антигистаминами
WO2006108295A1 (en) * 2005-04-11 2006-10-19 New Cell Formulations Ltd. Supplemental dietary composition for increasing muscle size and strength
AU2006235478B2 (en) 2005-04-12 2011-07-21 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
MX2007012778A (es) * 2005-04-12 2008-01-11 Elan Pharma Int Ltd Formulaciones de derivados de quinazolina nanoparticuladas.
CN101212954A (zh) * 2005-05-10 2008-07-02 伊兰制药国际有限公司 纳米粒氯吡格雷制剂
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
AU2006344711A1 (en) * 2005-05-16 2008-01-24 Alkermes Pharma Ireland Limited Nanoparticulate and controlled release compositions comprising a cephalosporin
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
DE602006012671D1 (de) 2005-06-03 2010-04-15 Elan Pharma Int Ltd Nanoteilchenförmige imatinib-mesylat-formulierungen
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP2009517485A (ja) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
ATE446742T1 (de) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
CN101237868A (zh) * 2005-06-13 2008-08-06 伊兰制药国际有限公司 纳米粒氯吡格雷和阿司匹林组合制剂
CA2608930A1 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
JP2008543862A (ja) * 2005-06-15 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子アゼルニジピン製剤
US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
GB0516549D0 (en) * 2005-08-12 2005-09-21 Sulaiman Brian Milling system
CA2622200A1 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
CA2628630A1 (en) * 2005-11-15 2007-05-24 Baxter International Inc. Compositions of lipoxygenase inhibitors
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
BRPI0620756B1 (pt) 2005-12-29 2021-06-01 Tersera Therapeutics Llc Derivados de aminoácido multicíclicos, formulação farmacêutica compreendendo os mesmos e seus usos para inibir a atividade de triptofano hidroxilase 1 (tph1)
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
TW200820991A (en) * 2006-07-10 2008-05-16 Elan Pharma Int Ltd Nanoparticulate sorafenib formulations
BRPI0714173A2 (pt) * 2006-07-12 2012-12-25 Elan Pharma Int Ltd composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
AU2007325628A1 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
EP2095816A1 (en) * 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety
KR20110007095A (ko) * 2008-03-21 2011-01-21 엘란 파마 인터내셔널 리미티드 이마티니브의 부위-특이적 전달을 위한 조성물 및 사용방법
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
EP2371880B1 (en) * 2008-12-26 2014-10-01 Asahi Glass Company, Limited Ethylene/tetrafluoroethylene copolymer granulation method
EP2389159A1 (en) 2009-01-22 2011-11-30 Noramco, Inc. Process for preparing particles of opioids and compositions produced thereby
EP2398499B1 (en) 2009-02-18 2017-09-06 Eyeon Particle Sciences LLC Bi-functional co-polymer use for ophthalmic and other topical and local applications
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
ES2699077T3 (es) 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
HUP0900384A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
EP2442794A1 (en) 2009-06-19 2012-04-25 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
HUP0900376A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
AU2010261510A1 (en) 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanostructured Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
WO2011056916A1 (en) 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
CN102753168A (zh) 2010-02-10 2012-10-24 莱西肯医药有限公司 用于治疗转移性骨病的色氨酸羟化酶抑制剂
EP2560624B1 (en) 2010-04-23 2018-07-04 KemPharm, Inc. Therapeutic formulation for reduced drug side effects
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
HUP1000325A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
HUP1000327A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation
US8574630B2 (en) 2010-09-22 2013-11-05 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CN103827233A (zh) 2011-09-16 2014-05-28 伊斯曼柯达公司 用于连续喷墨印刷机的墨组合物
WO2013059676A1 (en) 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
WO2013142258A1 (en) 2012-03-22 2013-09-26 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
US20130303763A1 (en) 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6360040B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013192493A1 (en) * 2012-06-21 2013-12-27 Phosphorex, Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014210543A1 (en) 2013-06-28 2014-12-31 Rexahn Pharmaceuticals, Inc. Nanoparticulate compositions and formulations of piperazine compounds
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
WO2015134608A1 (en) 2014-03-05 2015-09-11 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated 3-aminopyridine-2-carboxaldehyde particles
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
NZ767204A (en) 2014-08-18 2024-02-23 Alkermes Pharma Ireland Ltd Aripiprazole prodrug compositions
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
EP3285771A4 (en) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
MX2017013956A (es) 2015-05-01 2018-09-05 Cocrystal Pharma Inc Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
US11034701B2 (en) 2015-06-16 2021-06-15 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
US9573349B1 (en) 2015-07-30 2017-02-21 Eastman Kodak Company Multilayered structure with water-impermeable substrate
US9376582B1 (en) 2015-07-30 2016-06-28 Eastman Kodak Company Printing on water-impermeable substrates with water-based inks
KR20180082457A (ko) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
CA3014788A1 (en) 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
EP3513809B9 (en) 2016-09-13 2022-07-13 Kyowa Kirin Co., Ltd. Medicinal composition comprising tivozanib
US10226474B2 (en) 2017-01-09 2019-03-12 Temple University—Of The Commonwealth Sytem Of Higher Education Methods and compositions for treatment of non-alcoholic steatohepatitis
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
WO2020179701A1 (ja) * 2019-03-01 2020-09-10 塩野義製薬株式会社 異物を低減したナノ粒子組成物およびその製法
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
WO2021072325A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
EP3928772A1 (en) 2020-06-26 2021-12-29 Algiax Pharmaceuticals GmbH Nanoparticulate composition
CN113649135A (zh) * 2021-07-27 2021-11-16 惠州市银农科技股份有限公司 基于研磨补偿介质的热敏性原药研磨方法和农药制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273210C (zh) *
SU580211A1 (ru) * 1976-01-06 1977-11-15 Минский Опытно-Экспериментальный Завод "Продмаш" Устройство дл выплавки жира
US4775393A (en) * 1985-04-11 1988-10-04 The Standard Oil Company Autogenous attrition grinding
JPS62281953A (ja) * 1986-05-28 1987-12-07 旭光学工業株式会社 骨補填材
JPH0730263B2 (ja) * 1986-09-29 1995-04-05 ぺんてる株式会社 着色加工粉体
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JPH04166246A (ja) * 1990-10-31 1992-06-12 Matsushita Electric Ind Co Ltd 媒体撹拌ミル及び粉砕方法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles

Also Published As

Publication number Publication date
AU2550195A (en) 1995-12-18
ATE196601T1 (de) 2000-10-15
GR3035040T3 (en) 2001-03-30
MY112458A (en) 2001-06-30
EP0760653A1 (en) 1997-03-12
PT760653E (pt) 2001-03-30
CA2190966C (en) 2003-03-18
EP0760653B1 (en) 2000-09-27
US5862999A (en) 1999-01-26
DK0760653T3 (da) 2000-12-18
IL113852A0 (en) 1995-08-31
DE69518981T2 (de) 2001-03-01
DE69518981D1 (de) 2000-11-02
CA2190966A1 (en) 1995-11-30
WO1995031974A1 (en) 1995-11-30
ES2152401T3 (es) 2001-02-01
JPH10501709A (ja) 1998-02-17

Similar Documents

Publication Publication Date Title
TW384224B (en) Method of preparing submicron particles of a therapeutic or diagnostic agent
TW460297B (en) Continuous method of grinding pharmaceutical substances
KR100312798B1 (ko) 약제물질의분쇄방법
TW438606B (en) Use of purified surface modifiers to prevent particle aggregation during sterilization
FI108333B (fi) Menetelmõ nanopartikkelikoostumusten valmistamiseksi
US6555139B2 (en) Preparation of micron-size pharmaceutical particles by microfluidization
US5718919A (en) Nanoparticles containing the R(-)enantiomer of ibuprofen
JPH06227968A (ja) ナノ粒子を含む組成物及びその製造方法
JP2010241820A (ja) 保護被膜を有する再分散性超微粒状フィルムマトリックス
CA2206430A1 (en) Sugar base surfactant for nanocrystals
Chang et al. Dissolution characteristics of polycaprolactone-polylactide microspheres of chlorpromazine
JP2006193518A (ja) 新規なコア−シェル構造体
Patel et al. Improvement in the dissolution of poorly water soluble drug using media milling technique
Pandey et al. FORMULATION DEVELOPMENT & OPTIMIZATION OF PIOGLITAZONE HYDROCHLORIDE MICROSPHERES USING IONOTROPIC GELATION
JP2005053866A (ja) 化粧料
WO1996025181A1 (en) Process of preparing lymphography contrast agents

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MK4A Expiration of patent term of an invention patent